Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it has signed an agreement with U.K.-based ProStrakan Group plc (LSE: PSK) for the exclusive right to commercialize FORTESTA(TM) (testosterone gel) 2 percent in the United States.

26 Aug 2009

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Endo Pharmaceuticals announced today the commencement of a cash tender offer by its wholly-owned subsidiary, Endo Pharmaceuticals Solutions Inc., for any and all outstanding Ledgemont PhaRMA(SM) Secured 16% Notes due 2024 (the "Notes") of Ledgemont Royalty Sub LLC, Endo Pharmaceuticals Solutions Inc.'s wholly-owned subsidiary. The purpose of the tender offer is to acquire any and all Notes to reduce the consolidated interest expense of Endo.

26 Aug 2009

Positron forges Agent Agreement with Technology Imaging Services

Positron Corporation (OTCBB:POSC) (the “Company”), a molecular imaging solutions company focused on Nuclear Cardiology, announced today that they have executed an Agent Agreement with TIS – Technology Imaging Services. TIS offers a wide range of solutions for Nuclear Cardiology, Oncology, and Cardiac PET, including hot lab set up and products.

26 Aug 2009

Saint Vincent Hospital adds RF Surgical Detection System to surgical safety protocols

Saint Vincent Hospital in Worcester, Massachusetts has joined a growing number of over 100 hospitals nationwide to add the RF Surgical Detection System to its surgical safety protocols. This patented and FDA-approved technology uses a scanning wand that detects and signals an alert if any radio frequency tagged surgical sponges remain in a patient following surgery

26 Aug 2009

Lifeline Biotechnologies to establish a demonstration site for its First Warning System

Lifeline Biotechnologies, Inc. today announced that it is preparing to establish a demonstration site for its First Warning System to be located in Reno, Nevada.

26 Aug 2009

Gloucester Pharmaceuticals raises funds for the development of romidepsin

Gloucester Pharmaceuticals today announced that it has raised $29 million in a Series D financing. The proceeds will be used to support the ongoing development of romidepsin, a novel histone deacetylase (HDAC) inhibitor for the treatment of T-cell lymphomas and other hematologic malignancies.

26 Aug 2009

FDA establishes TPSAC to proceed further on the tobacco law

The U.S. Food and Drug Administration today announced an action regarding the implementation of the Family Smoking Prevention and Tobacco Control Act. The Agency has officially established the Tobacco Products Scientific Advisory Committee (TPSAC).

26 Aug 2009

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

BioDelivery Sciences International, Inc. today announced the issuance of United States Patent 7,579,019, which will provide additional patent exclusivity for both ONSOLIS and BDSI’s BEMA drug delivery technology platform until at least 2019.

26 Aug 2009

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Delcath Systems, Inc., a medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced today that it has exceeded 90% enrollment reaching 85 patients for its pivotal Phase III Metastatic Melanoma Trial.

25 Aug 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Diplomat Specialty Pharmacy announced today that its Diplomat Health Services Division is partnering with CareSource in Ohio to slow the progression of Chronic Kidney Disease (CKD), improve clinical outcomes and reduce healthcare costs associated with the disease. As the number of Americans with CKD continues to rise, CareSource is focused on the early identification and treatment of their patients with the illness.

25 Aug 2009

Phoenix Children’s Hospital adopts Eclipsys’ computerized physician order entry system

Eclipsys Corporation®, The Outcomes Company®, today announced that Phoenix Children’s Hospital, one of the 10 largest freestanding children’s hospitals in the country, has successfully completed an enterprise-wide activation of the company’s computerized physician order entry (CPOE) system, Sunrise Acute Care™.

25 Aug 2009

Research reveals the life-long detrimental impact of maternal smoking during pregnancy

A new study by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that the life-long effects of maternal smoking during pregnancy may occur through specific changes in DNA patterns.

25 Aug 2009

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc. (NASDAQ: APCVZ), announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market penicillin G potassium for Injection, USP, in two dosage strengths. Penicillin G is therapeutically equivalent to the reference drug PfizerPen™ G, which is marketed by the innovator Pfizer, Inc.

25 Aug 2009

Phase I/II trial of Amphinex uses photochemical internalisation approach

PCI Biotech Holding ASA, the Norwegian drug delivery company focusing on effective delivery of cancer therapeutics, today announced that the first patient has received treatment in the Phase I/II trial with the lead candidate Amphinex(R), which uses a new approach called photochemical internalisation.

25 Aug 2009

Rhode Island Hospital to identify a model for integrating screening and brief interventions for alcohol misuse

There are an estimated 7.6 million alcohol-related emergency department (ED) visits each year in the country. A first step in identifying an alcohol problem is screening all ED patients utilizing two well-researched screening tests.

24 Aug 2009

Encorium releases second-quarter 2009 results

Encorium Group, Inc. (Nasdaq: ENCO), a full service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical companies, today announced its financial results for the second quarter ended June 30, 2009.

24 Aug 2009

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Located in Guangzhou, Sun Yat-Sen University Cancer Center is one of China's renowned cancer research institutions, prominent in pre-clinical and clinical oncology research. The Sun Yat-Sen University Cancer Center was established to research anti-cancer treatments with a specific focus on developing major innovative drugs.

24 Aug 2009

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

BryanLGH Health System has selected Clinical Xpert CareFocus from Thomson Reuters to play an integral role in its ongoing efforts to improve clinical quality and patient safety.

24 Aug 2009

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted and has filed for review the Company's New Drug Application (NDA) for pixantrone as treatment for relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL). A Prescription Drug User Fee Act (PDUFA) date will be established by the FDA regarding the review of the pixantrone NDA by September 4th 2009.

24 Aug 2009

Oncology News and Research

Further Reading

Endo Pharmaceuticals gets exclusive rights to commercialize ProStrakan's FORTESTA in the U.S.

Endo Pharmaceuticals Solutions announces the beginning of cash tender offer

Positron forges Agent Agreement with Technology Imaging Services

Saint Vincent Hospital adds RF Surgical Detection System to surgical safety protocols

Lifeline Biotechnologies to establish a demonstration site for its First Warning System

Gloucester Pharmaceuticals raises funds for the development of romidepsin

FDA establishes TPSAC to proceed further on the tobacco law

U.S. Patent Office’s patent issuance provides extensive protection to BDSI's drug delivery technology platforms

Delcath Systems enrolls 85 patients for its pivotal Phase III Metastatic Melanoma Trial

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Diplomat Specialty Pharmacy and Ohio Caresource collaborate to develop Chronic Kidney Disease treatment

Phoenix Children’s Hospital adopts Eclipsys’ computerized physician order entry system

Research reveals the life-long detrimental impact of maternal smoking during pregnancy

FDA issues marketing approval for APP Pharmaceuticals' Penicillin G potassium for Injection, USP

Phase I/II trial of Amphinex uses photochemical internalisation approach

Rhode Island Hospital to identify a model for integrating screening and brief interventions for alcohol misuse

Encorium releases second-quarter 2009 results

Simcere to collaborate with Sun Yat-Sen University Cancer Center to research and develop anti-cancer drugs

Thomson Reuters to supply real-time clinical surveillance solution to Bryanlgh Health System

Cell Therapeutics' NDA for Pixantrone accepted by the FDA

eBook: Liquid biopsy in cancer research eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News